Miss Lara Graham

Publications

11 publications

Page 1 of 2

CD40L and IL-4 lymph node-associated signals protect B cells from rituximab-induced ADCC via KIR and NKG2A

Lara V. Graham, Russell B. Foxall, Margaret Ashton-Key, Salim I. Khakoo, Souraya Sayegh, Maria Leandro, Venkat R. Reddy, Mark S. Cragg & Matthew D. Blunt, 2026, Clinical and Experimental Immunology, 220(1)

DOI: 10.1093/cei/uxag001

Type: article

CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis

Lara V. Graham, Ludmila Horehajova, Marco V. Haselager, Jack G. Fisher, Jamie Lee Roos, Russell B. Foxall, Mel John, Kerry L. Cox, Robert J. Oldham, Martin C. Taylor, Margaret Ashton-Key, Ben Sale, Laura G. Bartlett, Ali Roghanian, Eric Eldering, Andres F. Vallejo, Francesco Forconi, Salim I. Khakoo, Mark S. Cragg & Matthew D. Blunt, 2025, Immunotherapy Advances, 5(1)

DOI: 10.1093/immadv/ltaf029

Type: article

Natural killer cells in anti-tumour immunity

Lara V. Graham & Matthew D. Blunt, 2024

DOI: 10.1016/b978-0-128-24465-4.00060-0

Type: bookChapter

KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies

Lara V. Graham, Jack G. Fisher, Amber D.P. Doyle, Ben Sale, Luis Del Rio , Albert J.E. French, Neema P. Mayor, Thomas R. Turner, Steven G.E. Marsh, Mark S. Cragg, Francesco Forconi, Salim Khakoo & Matthew D. Blunt, 2024, Frontiers in Oncology, 14

DOI: 10.3389/fonc.2024.1404051

Type: article

The nuclear export protein XPO1 provides a peptide ligand for natural killer cells

Matthew D. Blunt, Hayden Fisher, Ralf B. Schittenhelm, Berenice Mbiribindi, Rebecca Fulton, Sajida Khan, Laura Espana-Serrano, Lara V. Graham, Leidy Bastidas-Legarda, Daniel Burns, Sophie M.S. Khakoo, Salah Mansour, Jonathan W. Essex, Rochelle Ayala, Jayajit Das, Anthony W. Purcell & Salim I. Khakoo, 2024, Science Advances, 10(34)

DOI: 10.1126/sciadv.ado6566

Type: article

NK cells in the lymph nodes and their role in anti-tumour immunity

Lara V. Graham, Salim I. Khakoo & Matthew D. Blunt, 2024, Biomedicines, 12(8)

DOI: 10.3390/biomedicines12081667

Type: article

Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity

Jack G. Fisher, Lara V. Graham & Matthew D. Blunt, 2024, Oncotarget, 15(1), 501-503

DOI: 10.18632/oncotarget.28610

Type: letterEditorial

Targeting KIR as a novel approach to improve CAR-NK cell function

Lara V. Graham, Jack G. Fisher, Salim I. Khakoo & Matthew D. Blunt, 2023, Journal of Translational Genetics and Genomics, 7(4), 230-235

DOI: 10.20517/jtgg.2023.25

Type: article

XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression

Jack G. Fisher, Amber D.P. Doyle, Lara V. Graham, Shreyanshi Sonar, Ben Sale, Isla Henderson, Luis Del Rio, Peter W.M. Johnson, Yosef Landesman, Mark S. Cragg, Francesco Forconi, Christopher J. Walker, Salim I. Khakoo & Matthew D. Blunt, 2023, Leukemia, 37(10), 2036-2049

DOI: 10.1038/s41375-023-01984-z

Type: article

Disruption of the NKG2A:HLA-E immune checkpoint axis to enhance NK cell activation against Cancer

Jack G. Fisher, Amber D. P. Doyle, Lara V. Graham, Salim I. Khakoo & Matthew D. Blunt, 2022, Vaccines, 10(12)

DOI: 10.3390/vaccines10121993

Type: article

Connect with Lara

Publications